NASDAQ:RNLX Renalytix (RNLX) Stock Price, News & Analysis $0.26 +0.01 (+2.88%) (As of 07/5/2024 08:53 PM ET) Add Compare Share Share Today's Range$0.23▼$0.2750-Day Range$0.23▼$0.7952-Week Range$0.22▼$4.04Volume363,300 shsAverage Volume1.11 million shsMarket Capitalization$19.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Renalytix alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Renalytix Stock (NASDAQ:RNLX)Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.Read More RNLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNLX Stock News HeadlinesJune 27, 2024 | globenewswire.comRenalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting DeterminationJune 14, 2024 | globenewswire.comMedicare Issues Final Coverage Determination for kidneyintelX.dkdJuly 8, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.May 15, 2024 | investorplace.comRNLX Stock Earnings: Renalytix Misses EPS, Misses Revenue for Q3 2024May 15, 2024 | msn.comRenalytix AI GAAP EPS of -$0.08 beats by $0.01, revenue of $0.54M misses by $0.56MMay 15, 2024 | globenewswire.comRenalytix Reports Financial Results for Third Quarter of Fiscal Year 2024May 15, 2024 | markets.businessinsider.comRenalytix AI is about to announce its earnings — here's what Wall Street expectsMay 14, 2024 | markets.businessinsider.comRenalytix AI earnings: here's what Wall Street expectsJuly 8, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.May 9, 2024 | finance.yahoo.comRenalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15May 9, 2024 | globenewswire.comRenalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15April 28, 2024 | finance.yahoo.comRenalytix Plc (RNLX) Stock Price, News, Quote & History - Yahoo FinanceApril 17, 2024 | msn.comRenalytix files to sell 19.99M ordinary shares for holdersApril 9, 2024 | marketwatch.comRenalytix Sells Stock to Raise Up to $4 MlnApril 8, 2024 | globenewswire.comRenalytix Announces Financing with Expected Size of up to $4 MillionMarch 25, 2024 | investorplace.com3 Ridiculously Enticing Stocks to Buy for Under a BuckMarch 14, 2024 | stockhouse.comKidneyIntelX(TM) included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)March 14, 2024 | globenewswire.comKidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)See More Headlines Receive RNLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/07/2024Next Earnings (Estimated)9/26/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:RNLX CUSIPN/A CIK1811115 Webwww.renalytixai.com Phone44-20-3139-2910FaxN/AEmployees102Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,610,000.00 Net Margins-1,687.80% Pretax Margin-1,687.44% Return on Equity-1,008.88% Return on Assets-205.46% Debt Debt-to-Equity RatioN/A Current Ratio0.42 Quick Ratio0.42 Sales & Book Value Annual Sales$3.40 million Price / Sales5.84 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book1.71Miscellaneous Outstanding Shares77,180,000Free Float63,445,000Market Cap$19.84 million OptionableOptionable Beta2.78 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. James R. McCullough M.B.A. (Age 56)Chief Executive Officer Comp: $1.04MMr. Oliver James Sterling IIIChief Financial OfficerMr. Fergus Fleming (Age 56)Chief Technology Officer Mr. Salim Gulamabbas Hamir F.C.A.Company SecretaryKey CompetitorsBurning Rock BiotechNASDAQ:BNRPersonalisNASDAQ:PSNLEnzo BiochemNYSE:ENZExagenNASDAQ:XGNPsychemedicsNASDAQ:PMDView All CompetitorsInstitutional OwnershipPinnacle Associates Ltd.Sold 150,529 shares on 4/26/2024Ownership: 1.127%View All Institutional Transactions RNLX Stock Analysis - Frequently Asked Questions How have RNLX shares performed this year? Renalytix's stock was trading at $0.39 at the beginning of 2024. Since then, RNLX stock has decreased by 34.1% and is now trading at $0.2571. View the best growth stocks for 2024 here. How were Renalytix's earnings last quarter? Renalytix Plc (NASDAQ:RNLX) issued its earnings results on Wednesday, May, 15th. The company reported ($0.08) EPS for the quarter. The firm earned $0.54 million during the quarter. Renalytix had a negative net margin of 1,687.80% and a negative trailing twelve-month return on equity of 1,008.88%. When did Renalytix IPO? Renalytix (RNLX) raised $156 million in an initial public offering on Friday, July 17th 2020. The company issued 11,000,000 shares at $14.22 per share. J.P. Morgan and Stifel served as the underwriters for the IPO. How do I buy shares of Renalytix? Shares of RNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Renalytix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Renalytix investors own include Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CTI BioPharma (CTIC). This page (NASDAQ:RNLX) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. ...Stansberry Research | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renalytix Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Renalytix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNLX Stock Alerts